Roche’S Phase Iib Study Of Prasinezumab Missed Primary Endpoint, But Suggests Possible Benefit In Early-Stage Parkinson’S Disease
PADOVA study showed numerical delay in motor progression and positive trends on multiple secondary and exploratory endpoints </ ...